TS Picks: August 1, 2016

Anti-Zika potential of already-approved drugs; problems with animal studies; recognizing the contributions of grad students and postdocs

Tracy Vence
Aug 1, 2016

USDA, KEN HAMMOND

Selections from The Scientist’s reading list:
 

  • More than 20 of 774 US Food and Drug Administration–approved drugs screened by researchers at the University of Texas Medical Branch in Galveston and their colleagues showed some anti-Zika activities, the team reported last week (July 28) in Cell Host & Microbe. “The search for something that will work against Zika virus infection is so urgent that it makes sense to try existing drugs,” Lenore Pereira of the University of California, San Francisco, who was not involved with the work told STAT News. Last month, scientists in Brazil published a preprint showing that sofosbuvir, a drug approved for the treatment of hepatitis C, shows inbhits the Zika virus in vitro, and in May, another team also published a preprint suggesting that the antimalarial drug chloroquine may similarly help fight the infection.
     
  • Animal studies are often...

Interested in reading more?

TS Picks: August 1, 2016

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?